%D8%A5%D9%86%D9%81%D9%84%D9%8A%D9%83%D8%B3%D9%8A%D9%85%D8%A7%D8%A8%D8%A7%DB%8C%D9%86%D9%81%DB%8C%D9%84%DB%8C%DA%A9%D8%B3%DB%8C%D9%85%D8%A7%D8%A8InfliximabCategory:InfliximabInfliximabInfliximabInfliximabInfliximab%D8%A7%DB%8C%D9%86%D9%81%DB%8C%D9%84%DB%8C%DA%A9%D8%B3%DB%8C%D9%85%D8%A7%D8%A8InfliksimabiInfliximab%D7%A8%D7%9E%D7%99%D7%A7%D7%99%D7%99%D7%93Infliximab%E3%82%A4%E3%83%B3%E3%83%95%E3%83%AA%E3%82%AD%E3%82%B7%E3%83%9E%E3%83%96%EC%9D%B8%ED%94%8C%EB%A6%AD%EC%8B%9C%EB%A7%B5%D0%98%D0%BD%D1%84%D0%BB%D0%B8%D0%BA%D1%81%D0%B8%D0%BC%D0%B0%D0%B1InfliximabInfliksymabInfliximabe%D0%98%D0%BD%D1%84%D0%BB%D0%B8%D0%BA%D1%81%D0%B8%D0%BC%D0%B0%D0%B1InfliksimabInfliksimabInfliximab%D0%86%D0%BD%D1%84%D0%BB%D1%96%D0%BA%D1%81%D1%96%D0%BC%D0%B0%D0%B1InfliximabQ415264
about
sameAs
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy SubjectsEffects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisHigh Dose Interval Vitamin D Supplementation in Patients With IBD Receiving RemicadeMucosal Gene Expression Defects in IBDEffects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human ObesityTreatment With TNF Blockade, Infliximab, in Patients With MyositisStudy of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF BlockerBiomarkers of Anti-TNF Treatment in IBDEarly Serum Infliximab Levels in Severe Ulcerative Colitis.Korean College of Rheumatology Biologics RegistryA Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis CPsoriasis Longitudinal Assessment and Registry (PSOLAR)Infliximab and Methotrexate in Ankylosing SpondylitisTreatment of Refractory Diabetic Macular Edema With InfliximabPharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative ColitisTo Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid ArthritisRandomised Treatment of Acute Pancreatitis With Infliximab: Double-blind Multi-centre Trial (RAPID-I)EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative ColitisOne-year Persistence to Treatment of Participants Receiving Flixabi: a French Cohort StudyInfliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast CancerBeryllium Infliximab Study: Clinical Interventional TrialA Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type PsoriasisA Study of the Safety and Efficacy of Infliximab in Patients With PsoriasisCMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid ArthritisThe Effect of Infliximab on Sperm QualityA Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417)The Norwegian Drug Monitoring StudyKIDCARE (Kawasaki Disease Comparative Effectiveness Trial)The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's DiseaseAn Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn DiseaseInfliximab Therapy in Patients With Refractory Polymyalgia RheumaticaStudy Investigating Tailored Treatment With Infliximab for Active Crohn's DiseaseBiomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)Effect Of Anti TNF Alpha Therapy And Their Adverse Effects In Ankylosing Spondylitis In A North Indian Population
P4844
Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 casesPurulent Bronchitis Caused by Staphylococcus aureus in an Adolescent Receiving Infliximab for Crohn's Disease.Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel DiseasesTart Cherry Prevents Bone Loss through Inhibition of RANKL in TNF-Overexpressing MiceSuccessful use of TNFα blockade in a severe case of idiopathic non-granulomatous ulcerative jejunoileitis associated with thrombotic thrombocytopenic purpuraCrohn's-like acute severe colitis associated with Hermansky-Pudlak syndrome: A case reportINFLIXIMAB and ADALIMUMAB in Uveitic Macular EdemaBehçet's Syndrome and Nervous System InvolvementIndirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki diseaseHas infliximab influenced the course and prognosis of acute severe ulcerative colitis?Reduced CD27IgD B Cells in Blood and Raised CD27IgD B Cells in Gut-Associated Lymphoid Tissue in Inflammatory Bowel DiseaseLong-term efficacy and safety of infliximab and cyclosporine combination therapy for refractory uveoretinitis in Behçet's diseasePlasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case reportEarly introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitisPhysicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression systemSwitching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspectiveGenetic polymorphisms in tumour necrosis factor receptors () illustrate differential treatment response to TNFα inhibitors in patients with Crohn's diseaseEarly intestinal obstruction after infliximab therapy in Crohn's diseaseRecommendations for Initiating Systemic Therapy in Patients with PsoriasisA Review on the Effect of Tumor Necrosis Factor Inhibitors on Structural Progression in Early Axial Spondyloarthritis Using Magnetic Resonance ImagingAcute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximabFecal microbiota transplantation in refractory ulcerative colitis - a case reportLow TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel diseaseReliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels
P921
Q1274464-1151F48F-40BC-4E0C-B07C-2FA680497D86Q1472-25953EC5-F01D-4111-BCFB-2D41EDB146D2Q1477-9283263D-4AC4-41D5-AD7E-2403303ABD36Q1526459-6544518A-2690-48BF-A5A6-702DBA0A85BEQ170990-C3D9C1F8-5E74-4F35-8CF9-448FD6647005Q2012569-F0E83589-C230-4A62-A4EB-D3908C167D87Q2165411-7155E44E-971B-469C-8E98-37787688A0A7Q2453464-71C1A34F-1E5A-4AFD-8701-6BF6E2528479Q265936-DDBC26CF-23A1-4E88-9EC3-CFC7169EA254Q280027-F706B569-C79D-4DD5-8B0E-2DEB482A67B6Q432462-6F09F654-5039-47AC-81EB-3BF9C53E5697Q52849-DF6D3868-9B33-494C-A609-ADF1291558BDQ838966-18E99461-5AFE-41D6-BD08-C5F15B5760CEQ911427-32B98D99-2B81-4740-BA70-CE2D86B8D2B8
P2176
Q61864802-F7A61C22-450B-481E-ACC2-41F398AAF3CDQ61894258-3DD317C7-CAF1-480A-B3D8-19F42CC9CB9EQ61909100-5FB2D954-80AC-411F-95EC-122E1C345DD4Q61914991-C88392F8-7EE9-4484-A65F-F14F5F40ADCAQ61915351-C28CDC14-F9D2-4F87-B25B-146936EB1868Q61924904-F60DF29D-5A5E-4791-8C88-4289F7084E6CQ61932900-B6AD9DEB-5F36-4C37-AE98-5F064EAB7111Q61933752-982D6844-6ED5-4668-917A-94C399BAB973Q61933942-F7A9D0F6-B9DB-490B-BDA9-3F975F20D57AQ61938609-BA74E17B-2711-494D-A30D-0EE3B1440A60Q61975241-6ECCE6E4-1DD7-4C63-BB06-2214FD821D89Q61975254-EEFE528C-6EF1-44D5-95BB-FD5B0478AF0EQ61975787-210F1DE7-DBC7-4992-87C1-B264BEBC0861Q61975964-15917471-C6C2-4B5B-AECE-0780F794AF4FQ61979046-AA48B4CB-6D34-4FB2-816A-575FE3B52FB3Q61979576-963F2E2D-871F-4FEE-9F4B-A9DF4DF25E0EQ61979808-BFAC5448-AA56-4CC3-B336-6789B60A80B8Q61979947-545EC3B5-7FE6-466C-85D7-5745B5542CD6Q62031797-906B22F8-937A-4086-BD98-A72CE30E5519Q62042682-281D66B1-C8F5-4CF6-9928-EC9A5821A40EQ62054671-CA2FDF46-69FA-4818-8ACF-D22805BF7EF7Q62055056-928CD953-888C-4A7A-9823-CA0E5E19F5DFQ62062195-BC6894A0-B857-4217-99C1-F6BED67C420EQ62105020-1C454FD0-A1B0-414B-ABE6-51F160B9344AQ62105098-870FA778-42F3-4F13-BF99-5DA6A1918ECDQ62105667-178484A4-3429-4037-89AD-34AD9DF34F8BQ62105668-FCF2BEAD-3B94-4E0F-894C-DE339EC99A36Q62812640-7A2915D0-89B6-42BC-854A-A99BEB936991Q63062244-1970FA0D-AC9B-491C-AC1B-90164517AEBAQ63062732-8FB3FD85-FAFB-4B66-ADAC-2FE8DF159014Q63228774-DEC2B7BC-E16E-45D9-B66E-355A689BF23CQ63229551-23040079-2181-496D-BAB6-C024A80496D2Q63316505-C2E2C872-FB23-48CB-912B-4BA3D66B65ACQ63316647-E79A82D1-A8B5-411A-9486-33B15106FD4CQ63316655-4E50B7B0-1588-4A55-BC7F-B08B90D28E98Q63317163-D8293CE7-D734-4944-8B78-91228E898013Q63321669-FB40137D-4589-4547-9668-D43BA152DC72Q63322231-B6B867A6-A9BB-4789-85C0-57F89BF1BB84Q63335016-D1565CBD-719A-45D5-A82A-9C345E5A7654Q63335127-E09D0970-590D-4494-B60B-47BDA6FBEFF6
P4844
Q36699795-694F00CC-2E82-46EE-A7F2-FF4BD599EF04Q41333278-35150c7d-491c-52b7-e232-d1c3c87bcf31Q61808018-28744B84-B09F-4B8A-BED2-08EFF8265FADQ61811721-1ECFC206-F3EC-4F27-AE12-11424BDFE5F9Q64026822-0B66A8B2-8BCA-414F-8D26-D8E1AC98C213Q64040119-1155974F-CEB4-4B4F-B524-45A3ED07748FQ64043812-2DCBEFE6-6F8B-4C04-8A19-6FEDCBA480A4Q64045377-1B7DD050-7EA1-495E-A88F-074F75572CBAQ64052369-1284D60A-7AD1-4627-AC5F-8675BB48E67DQ64062261-BCE5C1B0-B819-4A4C-9BC9-D4C6F6BC36DCQ64062358-FC11B6A8-FBDE-4A5D-BC6D-D5E9811DB6D1Q64069537-F0AAC4BA-4306-40BC-83B4-0DA5A436DBCEQ64071181-792B741D-5C93-4752-B7D8-D6CF01EB17DAQ64085693-D9F5CCE4-3763-4D2B-B16C-D36A22027204Q64101864-A71ED5D2-E48D-427E-9D40-C6D6F7DC4232Q64115876-F38A31C4-E121-4E98-BEFC-1B98304C3D52Q64230865-1BB6F017-B30D-4274-A595-CCA447A9BD86Q64232394-EEC3DF17-22DB-497E-93B8-02DE6C72C7D9Q64245109-D80E94FA-95A3-47F9-8F89-8FB499153CBBQ64248201-3C980B5F-DAD1-4865-A20B-119A80BC8C6EQ64254899-EB5AC74D-E3E9-44F5-9A48-92138E04AC86Q64259275-C2A803B7-2405-4803-B0CB-ACA1AD493CDAQ64261195-7ADA1D14-879A-45E3-BD3E-10CD59CF6477Q64326944-AF1DCA18-309F-416A-A353-30E661A62250
P921
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
compositum chemicum
@la
name
Gammaglobulina
@eu
Infliksimab
@sh
Infliksimab
@sr
Infliksimabi
@fi
Infliksymab
@pl
Infliximab
@cs
Infliximab
@de
Infliximab
@it
Infliximab
@nl
Infliximab
@sv
type
label
Gammaglobulina
@eu
Infliksimab
@sh
Infliksimab
@sr
Infliksimabi
@fi
Infliksymab
@pl
Infliximab
@cs
Infliximab
@de
Infliximab
@it
Infliximab
@nl
Infliximab
@sv
altLabel
170277-31-3
@fr
C6428H9912N1694O1987S46
@it
CA2 ????
@en
Ig gamma-1 chain C region
@en
Infliksimab
@pl
Infliximab
@fi
Infliximab
@pl
Remicade
@de
Remicade
@fr
Remicade
@he
prefLabel
Gammaglobulina
@eu
Infliksimab
@sh
Infliksimab
@sr
Infliksimabi
@fi
Infliksymab
@pl
Infliximab
@cs
Infliximab
@de
Infliximab
@it
Infliximab
@nl
Infliximab
@sv
P2175
P2868
P31
P3780
P486
P592
P6366
P646
P665
P1417
topic/infliximab
P2115
N0000148580
P2175
P2275
Infliximab
@en
P231
170277-31-3
P267
P2840
P3117
DTXSID9040504
P3221
subject/remicade-drug